vs
Side-by-side financial comparison of MOVADO GROUP INC (MOV) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
MOVADO GROUP INC is the larger business by last-quarter revenue ($186.1M vs $177.4M, roughly 1.0× Pacira BioSciences, Inc.). MOVADO GROUP INC runs the higher net margin — 5.1% vs 1.6%, a 3.5% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs 1.9%). Over the past eight quarters, MOVADO GROUP INC's revenue compounded faster (2.9% CAGR vs -0.2%).
Movado is a luxury American watch brand originally founded in 1881 in Switzerland. Movado means "movement" in Esperanto. The watches are known for their signature metallic dot at 12 o'clock and minimalist style; the company is best known for its Museum Watch.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
MOV vs PCRX — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $186.1M | $177.4M |
| Net Profit | $9.6M | $2.9M |
| Gross Margin | 54.3% | — |
| Operating Margin | 6.3% | 3.9% |
| Net Margin | 5.1% | 1.6% |
| Revenue YoY | 1.9% | 5.0% |
| Net Profit YoY | 89.8% | — |
| EPS (diluted) | $0.42 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $186.1M | $196.9M | ||
| Q3 25 | $161.8M | $179.5M | ||
| Q2 25 | $131.8M | $181.1M | ||
| Q1 25 | $181.5M | $168.9M | ||
| Q4 24 | $180.5M | $187.3M | ||
| Q3 24 | $157.0M | $168.6M | ||
| Q2 24 | $134.4M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $9.6M | — | ||
| Q3 25 | $3.0M | $5.4M | ||
| Q2 25 | $1.4M | $-4.8M | ||
| Q1 25 | $8.1M | $4.8M | ||
| Q4 24 | $4.8M | — | ||
| Q3 24 | $3.5M | $-143.5M | ||
| Q2 24 | $2.0M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 54.3% | 79.5% | ||
| Q3 25 | 54.1% | 80.9% | ||
| Q2 25 | 54.1% | 77.4% | ||
| Q1 25 | 54.2% | 79.7% | ||
| Q4 24 | 53.5% | 78.7% | ||
| Q3 24 | 54.3% | 76.9% | ||
| Q2 24 | 54.3% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 6.3% | 1.2% | ||
| Q3 25 | 2.5% | 3.5% | ||
| Q2 25 | 0.2% | 4.7% | ||
| Q1 25 | 5.1% | 1.2% | ||
| Q4 24 | 3.3% | 13.2% | ||
| Q3 24 | 1.7% | -82.8% | ||
| Q2 24 | 1.6% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 5.1% | — | ||
| Q3 25 | 1.8% | 3.0% | ||
| Q2 25 | 1.1% | -2.7% | ||
| Q1 25 | 4.4% | 2.8% | ||
| Q4 24 | 2.7% | — | ||
| Q3 24 | 2.2% | -85.1% | ||
| Q2 24 | 1.5% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.42 | $0.05 | ||
| Q3 25 | $0.13 | $0.12 | ||
| Q2 25 | $0.06 | $-0.11 | ||
| Q1 25 | $0.36 | $0.10 | ||
| Q4 24 | $0.21 | $0.38 | ||
| Q3 24 | $0.15 | $-3.11 | ||
| Q2 24 | $0.09 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $183.9M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $497.5M | $653.9M |
| Total Assets | $751.9M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $183.9M | $238.4M | ||
| Q3 25 | $180.5M | $246.3M | ||
| Q2 25 | $203.1M | $445.9M | ||
| Q1 25 | $208.5M | $493.6M | ||
| Q4 24 | $181.5M | $484.6M | ||
| Q3 24 | $198.3M | $453.8M | ||
| Q2 24 | $225.4M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $497.5M | $693.1M | ||
| Q3 25 | $489.9M | $727.2M | ||
| Q2 25 | $493.2M | $757.8M | ||
| Q1 25 | $481.3M | $798.5M | ||
| Q4 24 | $491.3M | $778.3M | ||
| Q3 24 | $492.0M | $749.6M | ||
| Q2 24 | $489.6M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $751.9M | $1.3B | ||
| Q3 25 | $748.7M | $1.3B | ||
| Q2 25 | $747.2M | $1.5B | ||
| Q1 25 | $729.2M | $1.6B | ||
| Q4 24 | $747.2M | $1.6B | ||
| Q3 24 | $742.5M | $1.5B | ||
| Q2 24 | $736.0M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $12.3M | — |
| Free Cash FlowOCF − Capex | $11.6M | — |
| FCF MarginFCF / Revenue | 6.2% | — |
| Capex IntensityCapex / Revenue | 0.4% | — |
| Cash ConversionOCF / Net Profit | 1.28× | — |
| TTM Free Cash FlowTrailing 4 quarters | $35.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $12.3M | $43.7M | ||
| Q3 25 | $-3.8M | $60.8M | ||
| Q2 25 | $-7.2M | $12.0M | ||
| Q1 25 | $39.1M | $35.5M | ||
| Q4 24 | $-4.7M | $33.1M | ||
| Q3 24 | $-17.8M | $53.9M | ||
| Q2 24 | $-18.1M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $11.6M | $43.5M | ||
| Q3 25 | $-5.1M | $57.0M | ||
| Q2 25 | $-8.7M | $9.3M | ||
| Q1 25 | $37.5M | $26.9M | ||
| Q4 24 | $-7.2M | $31.0M | ||
| Q3 24 | $-20.1M | $49.8M | ||
| Q2 24 | $-19.7M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 6.2% | 22.1% | ||
| Q3 25 | -3.1% | 31.7% | ||
| Q2 25 | -6.6% | 5.1% | ||
| Q1 25 | 20.7% | 15.9% | ||
| Q4 24 | -4.0% | 16.6% | ||
| Q3 24 | -12.8% | 29.6% | ||
| Q2 24 | -14.7% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.4% | 0.1% | ||
| Q3 25 | 0.8% | 2.2% | ||
| Q2 25 | 1.2% | 1.5% | ||
| Q1 25 | 0.9% | 5.1% | ||
| Q4 24 | 1.4% | 1.1% | ||
| Q3 24 | 1.5% | 2.4% | ||
| Q2 24 | 1.2% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.28× | — | ||
| Q3 25 | -1.27× | 11.20× | ||
| Q2 25 | -5.08× | — | ||
| Q1 25 | 4.86× | 7.37× | ||
| Q4 24 | -0.98× | — | ||
| Q3 24 | -5.14× | — | ||
| Q2 24 | -8.97× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MOV
| Other | $81.4M | 44% |
| Owned Brands Category | $46.0M | 25% |
| Sales Channel Directly To Consumer | $35.3M | 19% |
| Company Stores | $23.4M | 13% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
